AmberGen receives US Patent 8,148,062 for detecting disease causing genetic mutations such as breast and colorectal cancer using affinity tags in translated nascent proteins
AmberGen awarded 3-year Phase II SBIR grant for discovery of tumor autoantigen biomarkers using Bead-AMS™ proteomic array technology
AmberGen and Massachusetts General Hospital license the use of two novel autoantigen biomarkers for autoimmune liver disease to INOVA Diagnostics http://www.marketwired.com/press-release/ambergen-mass-general-license-two-novel-autoantigen-biomarkers-autoimmune-liver-disease-1631270.htm
AmberGen receives US Patent 8,114,587 for analyzing DNA mutations in fecal samples for colorectal cancer detection
Agreement between AmberGen and SomaLogic® enables use of photocleavable reagent in SOMAmer® technology used to discover new biomarkers AmberGen-SomaLogic Press Release
AmberGen awarded Phase I SBIR grant for use of photocleavable peptide and peptoid bead-libraries in screening biomolecular interactions
AmberGen receives US Patent 7,897,335 for electrophoresis-free methods of high sensitivity detection of chain truncation mutations using tagged translated nascent proteins
AmberGen wins Illumina’s VeraCode™ Assay Design Challenge for development of a multiplex colorectal cancer diagnostic
Promega distributes AmberGen’s fluorescent tRNA based protein engineering technology https://www.promega.com/products/protein-expression/protein-labeling-and-detection/fluorotect-greenlys-in-vitro-translation-labeling-system/
